Laboratory Co. of America Holdings (NYSE:LH - Free Report) - Research analysts at Leerink Partnrs upped their Q2 2025 earnings estimates for shares of Laboratory Co. of America in a research report issued on Tuesday, April 29th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $4.14 per share for the quarter, up from their prior estimate of $4.11. The consensus estimate for Laboratory Co. of America's current full-year earnings is $16.01 per share. Leerink Partnrs also issued estimates for Laboratory Co. of America's Q3 2025 earnings at $4.12 EPS and Q4 2025 earnings at $4.05 EPS.
Other equities analysts have also recently issued reports about the company. Citigroup upgraded Laboratory Co. of America from a "neutral" rating to a "buy" rating and raised their price objective for the company from $250.00 to $300.00 in a research note on Tuesday, March 4th. UBS Group decreased their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. StockNews.com lowered Laboratory Co. of America from a "buy" rating to a "hold" rating in a report on Friday, April 18th. Piper Sandler lifted their price target on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Robert W. Baird upped their price objective on Laboratory Co. of America from $253.00 to $267.00 and gave the company an "outperform" rating in a research note on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $267.85.
Read Our Latest Research Report on LH
Laboratory Co. of America Stock Down 0.3 %
Shares of Laboratory Co. of America stock traded down $0.76 on Friday, hitting $246.90. The company had a trading volume of 677,658 shares, compared to its average volume of 639,304. The stock has a market capitalization of $20.66 billion, a price-to-earnings ratio of 27.99, a P/E/G ratio of 1.71 and a beta of 0.82. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. Laboratory Co. of America has a 1 year low of $191.97 and a 1 year high of $258.59. The stock has a 50 day moving average of $234.29 and a 200-day moving average of $236.11.
Laboratory Co. of America (NYSE:LH - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.11. The firm had revenue of $3.35 billion for the quarter, compared to the consensus estimate of $3.41 billion. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.68 earnings per share.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Barclays PLC raised its position in Laboratory Co. of America by 11.8% in the 3rd quarter. Barclays PLC now owns 620,721 shares of the medical research company's stock worth $138,718,000 after purchasing an additional 65,356 shares during the period. Virtu Financial LLC bought a new stake in shares of Laboratory Co. of America in the 3rd quarter valued at about $604,000. World Investment Advisors LLC purchased a new stake in Laboratory Co. of America during the 3rd quarter valued at about $5,955,000. Wilmington Savings Fund Society FSB grew its position in Laboratory Co. of America by 34.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 25,847 shares of the medical research company's stock worth $5,776,000 after acquiring an additional 6,651 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Laboratory Co. of America by 27.3% in the 3rd quarter. Franklin Resources Inc. now owns 20,837 shares of the medical research company's stock worth $4,519,000 after purchasing an additional 4,468 shares during the period. Institutional investors own 95.94% of the company's stock.
Insider Buying and Selling at Laboratory Co. of America
In related news, EVP Der Vaart Sandra D. Van sold 1,314 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $251.30, for a total value of $330,208.20. Following the transaction, the executive vice president now directly owns 2,171 shares in the company, valued at approximately $545,572.30. This represents a 37.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kerrii B. Anderson sold 500 shares of Laboratory Co. of America stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $255.63, for a total transaction of $127,815.00. Following the sale, the director now owns 13,166 shares of the company's stock, valued at approximately $3,365,624.58. The trade was a 3.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,987 shares of company stock valued at $4,171,895 in the last quarter. 0.84% of the stock is currently owned by corporate insiders.
Laboratory Co. of America Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.17%. Laboratory Co. of America's dividend payout ratio is currently 33.29%.
About Laboratory Co. of America
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Further Reading
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
